Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Liquid biopsy for non-invasive molecular characterization and measurable residual disease analysis in multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

BFBenedikt FärberEDEva DazertLRLuna Reifenrath

Discussion

Loading...

Member takes

Overview

Proof-of-concept study shows liquid biopsy using ctDNA enhances molecular characterization in multiple myeloma, indicating improved disease monitoring.

Key Points

  • This research aims to evaluate liquid biopsy's effectiveness in molecular characterization and measurable residual disease assessment in multiple myeloma.
  • Assessed biomarkers using next generation flow cytometry and targeted sequencing in 20 multiple myeloma patients.
  • Conducted ctDNA analysis from plasma alongside bone marrow samples to evaluate disease burden.
  • Utilized metabolomics and glycoproteomics to identify changes in protein and cytokine profiles across treatment responses.
  • ctDNA identified molecular markers in both NGF-positive and NGF-negative patients, revealing deeper insights into clonal evolution.
  • Tracking ctDNA displayed persistent positivity in progressive disease and clearance in responsive cases.
  • Distinct plasma proteomic profiles indicated differences between active and controlled disease states, supporting potential predictive modeling.

Cite This Study

Färber et al. (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d7d1https://doi.org/10.1182/blood-2025-2208
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Pilot study of cell-free DNA (cfDNA) for measurable residual disease monitoring following autologous hematopoietic cell transplant in multiple myeloma2025 · 2 citations
  2. 2Circulating Tumor DNA As a Minimally Invasive Predictor of Early Relapse in Multiple Myeloma2024 · 2 citations
  3. 3Minimally invasive characterization of peripheral blood measurable residual disease in multiple myeloma using high‐sensitivity detection of ctDNA by next‐generation sequencing2026 · 2 citations
  4. 4Integrated cell-free DNA and RNA sequencing recapitulates bone marrow genomic and transcriptomic alterations in multiple myeloma2025 · 1 citations
  5. 5Whole genome sequencing of cell-free DNA for assessment of minimal residual disease in high-risk smoldering multiple myeloma2025